Lundbeck

37,74 DKK +0,96 %

Ole ensimmäinen seuraaja

www.lundbeck.com/global

Lundbeck is a pharmaceutical company. The greatest focus is found in research on psychiatric and neurotic disorders, which includes the treatment of depression, schizophrenia, Alzheimer's and Parkinson's syndrome. The company conducts research, development and distribution of medicines where the customer base can be found on a global level. The company was originally founded in 1915 and has its headquarters in Valby.

Liikevaihto

18,25 mrd.

EBIT %

15,63 %

P/E -luku

19,55

Osinkotuotto %

1,54 %

Tavoitehinta

Suositus

Päivitetty

NASDAQ Copenhagen

HLUN B

Päivän matalin / päivän korkein hinta

36,92 / 37,98 DKK

Markkina-arvo

36,62 mrd. DKK

Vaihto

26,21 milj. DKK

Vaihtomäärä, kappaletta

698 t.

Pörssikalenteri

Osavuosikatsaus

08.11.2023

Näytä Kaikki sisältötyypit

H. Lundbeck A/S: Lundbeck presents clinical advances in migraine prevention with positive trial results at international headache congress

Lehdistötiedote14.09.2023

Lundbeck

Pörssikalenteri

H. Lundbeck A/S: Lundbeck presents clinical advances in migraine prevention with positive trial results at international headache congress

H. Lundbeck A/S: Lundbeck and Otsuka announce topline results from two phase III trials of brexpiprazole as combination therapy with sertraline for the treatment of Post-Traumatic Stress Disorder in adults

H. Lundbeck A/S: Lundbeck announces changes to Executive Management

H. Lundbeck A/S: Lundbeck's revenue increased by 13% (+10% CER) to DKK 10 billion in the first six months of 2023

H. Lundbeck A/S: The Board of Directors initiates CEO succession

H. Lundbeck A/S: Long-term benefits of Vyepti[®] confirmed by new data presented at the annual meeting of the American Headache Society

Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties

H. Lundbeck A/S: Lundbeck and Otsuka announce U.S. Food and Drug Administration (FDA) approval of sNDA for Rexulti® (brexpiprazole) for the treatment of agitation associated with dementia due to Alzheimer's Disease

H. Lundbeck A/S: Lundbeck's sales increased by 15% (+11% at constant exchange rates) to DKK 5 billion in the first quarter of 2023

H. Lundbeck A/S: Lundbeck announces positive phase II Proof of Concept results with Lu AG09222 in migraine prevention

H. Lundbeck A/S: Lundbeck held its Annual General Meeting on 21 March 2023 at the company's registered office

H. Lundbeck A/S: Notice of Annual General Meeting

Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties

Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties

Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties

H. Lundbeck A/S: Lundbeck Annual Report 2022

H. Lundbeck A/S: Lundbeck delivers record revenue of DKK 18.2 billion and grows 12% in 2022

H. Lundbeck A/S: Lundbeck announces financial guidance for 2023 and mid-term financial targets that build on very strong 2022 performance

H. Lundbeck A/S: Thomas Gibbs to join Lundbeck as Executive Vice President and Head of Lundbeck in the United States

H. Lundbeck A/S: Lundbeck announces FDA acceptance and priority review of sNDA for brexpiprazole for the treatment of agitation associated with Alzheimer's dementia